ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Search by Abstract Number Results

  • Abstract Number: 0457 • ACR Convergence 2024

    Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis

    Joshua Baker1, George Reed2, Geoffrey Thiele3, Dimitrios Pappas4, christina Charles-Schoeman5, Monica Guma6, Leslie Harrold7, Jeffrey Curtis8 and Joel Kremer9, 1Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 2University of Massachusetts Chan Medical School, Worcester, MA, 3University of Nebraska Medical Center, Omaha, NE, 4CorEvitas, New York, NY, 5UCLA Medical Center, Santa Monica, CA, 6UCSD, La Jolla, CA, 7CorEvitas, Northborough, MA, 8University of Alabama at Birmingham, Hoover, AL, 9The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
  • Abstract Number: 0457 • ACR Convergence 2023

    Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival

    Deanna Jannat-Khah1, Jeffrey R Curtis2, Fenglong Xie3, Ashish Saxena4 and Anne Bass5, 1Hospital For Special Surgery, New York, NY, 2Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
  • Abstract Number: 0457 • ACR Convergence 2022

    A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis

    Jan Schirmer1, Beatriz Sanchez-Alamo2, Sara Monti3, Bernhard Hellmich4, David Jayne5 and Gunnar Tomasson6, 1University Medical Center Schleswig-Holstein, Kiel, Germany, 2Lund University, Skåne University Hospital, Lund, Sweden, 3Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, 4Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, 5University of Cambridge, Cambridge, United Kingdom, 6Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland

    Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
  • Abstract Number: 0457 • ACR Convergence 2021

    Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination

    Michael Paley1, Parakkal Deepak2, Wooseob Kim2, Monica Yang3, Alex Carividi3, Emanuel Demissie3, Alia A. El-Qunni,2, Alem Haile2, Katherine Huang2, Baylee Kinnett2, Mariel Liebeskind2, Zhouming Liu2, Lily E. McMorrow2, Diana Paez3, Niti Pawar3, Dana Perantie2, Rebecca E. Schriefer2, Shannon Sides2, Mahima Thapa2, Sewuese Akuse4, Samantha Burdess2, Abbey Rose2, Lynne Mitchell2, Salim Chahin2, Matthew Ciorba2, Jonathan Graf5, Patricia Katz3, Mehrdad Matloubian3, Jane O'Halloran2, Rachel Presti2, Gregory Wu2, Sean Whelan2, William Buchser2, Lianne Gensler6, Mary Nakamura7, Ali H Ellebedy2 and Alfred Kim2, 1Washington University in St. Louis, Olivette, MO, 2Washington University School of Medicine, St. Louis, MO, 3University of California San Francisco, San Francisco, CA, 4Washington University School of Medicine, St Louis, MO, 5Ucsf, San Francisco, CA, 6Department of Rheumatology, University of California San Francisco, San Francisco, CA, 7UCSF/SFVAHCS, San Francisco, CA

    Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
  • Abstract Number: 0457 • ACR Convergence 2020

    Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients

    Julia Harris1, Michael Holland2, Emily Fox2, Amy Ivy3, Maria Ibarra2, Cara Hoffart2, Jordan Jones2, Leslie Favier4 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO, 3Children's Mercy Kansas City, Kansas City, 4Children's Mercy Kansas City, Leawood, KS

    Background/Purpose: The Centers for Disease Control and Prevention recommends pneumococcal vaccination of high-risk patients, including patients on iatrogenic immunosuppression. Many patients seen in the rheumatology…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology